Literature DB >> 19042586

Heterogeneous impact of methadone on the QTc interval: what are the practical implications?

Mori J Krantz1.   

Abstract

Methadone is associated with prolongation of the corrected QT interval (QTc) and torsade de pointes in case series, cross sectional studies, a prospective cohort study, and one randomized trial. It has recently been suggested that methadone promoted sudden cardiac death based on the absence of structural heart disease in an autopsy cohort. Given increasing data linking methadone to arrhythmia, clinicians must understand whether the relationship is causal, and if so, anticipate the expected frequency of QTc interval prolongation in their patients. To date has not been well characterized. To assess the impact of methadone on the QTc interval, electrocardiography at baseline and 6 months after methadone induction was evaluated from a previously published prospective cohort study of heroin addicts. Absolute increases above categorical QTc thresholds and the proportion with QTc interval increases exceeding 30 and 60 msec were tabulated. Among 151 subjects, 76% experienced an increase in QTc, whereas 24% had no change or a decrease. The proportion exceeding 450 msec increased from 7% at baseline to 19% at 6 months; those exceeding 500 msec increased from 0% to 2%. Although 18% of subjects had an increase in QTc of 30 msec, only 3% had an increase exceeding 60 msec. Most methadone-treated patients develop QTc prolongation. However, critical QTc prolongation (exceeding 500 msec or increases exceeding 60 msec) occurred infrequently. This highlights the heterogeneity of QTc interval changes and measurement variability but also implies that electrocardiography screening among opioid dependent patients would only occasionally require methadone discontinuation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19042586     DOI: 10.1080/10550880802324317

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  8 in total

1.  Changes of QTc interval after opioid switching to oral methadone.

Authors:  Sebastiano Mercadante; Giovanna Prestia; Claudio Adile; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2013-08-15       Impact factor: 3.603

Review 2.  Pharmacogenetics of Opioid Use Disorder Treatment.

Authors:  Richard C Crist; Toni-Kim Clarke; Wade H Berrettini
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

3.  Patterns of care and side effects for patients prescribed methadone for treatment of chronic pain.

Authors:  Tara A Macey; Melissa B Weimer; Elizabeth M Grimaldi; Steven K Dobscha; Benjamin J Morasco
Journal:  J Opioid Manag       Date:  2013 Sep-Oct

Review 4.  Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?

Authors:  Anita Srivastava; Meldon Kahan; Maya Nader
Journal:  Can Fam Physician       Date:  2017-03       Impact factor: 3.275

Review 5.  Effects of opioid receptor agonist and antagonist medications on electrocardiogram changes and presentation of cardiac arrhythmia: review article.

Authors:  Farshid Etaee; Morgan Tobin; Suchith Vuppala; Alireza Komaki; Brian P Delisle; Luigi Di Biase; John N Catanzaro; Andrea Natale; Claude S Elayi
Journal:  J Interv Card Electrophysiol       Date:  2021-10-21       Impact factor: 1.900

Review 6. 

Authors:  Anita Srivastava; Meldon Kahan; Maya Nader
Journal:  Can Fam Physician       Date:  2017-03       Impact factor: 3.275

7.  Assessment and treatment of abuse risk in opioid prescribing for chronic pain.

Authors:  Robert N Jamison; Juliana Serraillier; Edward Michna
Journal:  Pain Res Treat       Date:  2011-10-11

Review 8.  Intersection of chronic pain treatment and opioid analgesic misuse: causes, treatments, and policy strategies.

Authors:  Amy Wachholtz; Gerardo Gonzalez; Edward Boyer; Zafar N Naqvi; Christopher Rosenbaum; Douglas Ziedonis
Journal:  Subst Abuse Rehabil       Date:  2011-08-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.